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Abstract 
This research aimed to synthesize and characterize Zn
2+
-ligand complexes that have the 
same zinc coordination environment as in histone deacetylase (HDAC) and other important zinc-
dependent enzymes. Mimicking the structural and the functional properties of Zn
2+
-enzymes will 
allow us to understand the binding reactivity between Zn
2+
 and small molecule enzyme 
inhibitors. The new understanding will help to develop new approaches to target disease states 
such as cancer. A variety of Zn
2+
 binary complexes have been synthesized and their interactions 
with inhibitors such as suberanilohydroxamic acid (SAHA) and 8-Hydroxyquinoline (8HQ) have 
been studied using 
1
H NMR, UV-Vis, and fluorescence spectroscopies.
 
Attempts were made to 
mimic the structure of Zn
2+
-metalloenzyme active sites by exploring several different supporting 
ligands to model enzyme active sites. We endeavored to mimic an “O2N” ligand set of HDAC by 
using reported Zn
2+
-complexes ligated by Bis(phenolato)amine (H2L1), Bis(2-picolyl) amine 
(BPA, L2), hydrotris(3-phenyl-5-methylpyrazol-1-yl) (Tp
Ph,Me
, L3), and a similar neutral ligand 
(L4). The binding constants of the ligands with zinc were estimated using UV-Vis studies and 
calculations based on equilibrium expressions. This data was compared with previously reported 
data using other methods such as potentiometry and isothermal titration calorimetry.   
Once the zinc-ligand complexes were obtained, they were examined for mimicking zinc 
active sites. Attempts were made to study the interaction of inhibitors with the zinc center using 
1
H NMR, UV-Vis, and fluorescence spectroscopies. In addition, the functional properties of the 
mimicked structure were explored by attempting to cleave the amide group of a model substrate 
for HDAC, N-acetylbenzylamine. Although the Zn
2+
 species were not active, Al
 3+ 
was observed 
to cleave the amide group at high temperature after extended periods of time. The zinc-ligand 
 
 
 
9 
structures were also examined using computational methods to support the experimental data. 
The results of this work are valuable complementary data to previously reported ITC data and 
the known biological systems. 
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Chapter 1. Introduction 
Zinc plays a variety of critical roles in biology. An average adult human body contains 3 
grams of zinc, present in all body muscle tissue, and in higher concentrations in various organs 
such as prostate and eye tissue (retina and choroids).
1  
Zinc is the second most abundant 
transition metal in our bodies after iron.
2
  In medicine, zinc is important because it has been 
shown to help prevent the effects of infectious diseases such as malaria and pneumonia, and to 
shorten the length of common cold in adults.
1
  At a molecular biology level, zinc is an essential 
component in approximately 300 enzymes within six main classes: oxidoreductases, transferases, 
hydrolases, lyases, and isomerases.
3,4
 These zinc-dependent enzymes play a significant role in 
the progression of human diseases. For example, zinc is indispensable for the effective growth 
and development of cancer cells. Thus, zinc-containing enzymes are potential targets for the 
treatment of cancer in humans. 
   In metal-based enzymes, the binding between the metal in the active site and various 
ligands such as substrates or inhibitors depends on many factors. It is often useful to invoke the 
“Hard-soft acid-base” (HSAB) theory, in which strong bonding occurs when a hard acid and 
hard base or a soft acid and soft base interact. Zinc is a “borderline” metal, which means the 
interactions between the Zn and both hard and soft donor atoms in the ligand are equally 
favorable.
4
 Likewise, the divalent d
10
 Zn
2+
 ion is exceptionally stable with respect to oxidation 
and reduction under biological conditions, and so does not participate in redox reactions, as 
compared to the redox-active biological metals Mn, Fe, and Cu. Zinc often plays a role of 
activating reagents via donor-acceptor interactions. One classic example of an enzyme with a 
zinc atom in its active site is carbonic anhydrase (CA). The carbonic anhydrase enzymes are 
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oldest known class of Zn metalloenzymes, which was discovered in 1940 by Brinkman et al 
(Figure. 1.1).
5
  
 
Figure 1. 1. Carbonic anhydrase II (CA). Image from the RCSB PDB of PDB ID 5J8Z, and 
generated by PyMol. The upper Figure shows the binding between the Zn and three histidines, 
and the second figure shows a carbonic anhydrase inhibitor binding with Zn
2+
.
1 
 
The CA enzyme contain four ligands binding with Zn
2+
 in the resting state of the catalyst, three 
Histidine residues (His) and a nucleophilic, activated hydroxide molecule occupies the fourth 
coordination site, providing a distorted tertahedral geometry.
6
 Human CA plays an important role 
in regulation the pH and fluid balance in different parts of human body.
7
 It catalyzes the 
reversible hydration of bicarbonate ion to form carbon dioxide, as per the following reaction: 
CO2 + H2O ⇌ HCO
−
3 + H
+
 
The inhibition of human CA can have harmful effects on the body in the form of acidosis as 
blood pH homeostasis is disrupted.
8
 The tetrahedral coordination in Zn and the surrounding 
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amino acids enhance both the Lewis acidity of the zinc center and the Brønsted acidity of a 
coordinated water molecule.
6
 Ligand field stabilization effects do not influence zinc complexes 
due to the d
10
 configuration of Zn
2+
, and so coordination number and geometry are quite flexible 
and are only affected by ligand size and charge. Hydrolytic Zn-enzymes are capable of 
hydrolyzing a variety of strong bonds, such as hydrating CO2 in carbonic anhydrase, cleaving 
amide bonds (RC(O)-NHR′), or cleaving a phosphate bond.1  
Amide bonds are very stable in biology, but they can be hydrolyzed by Zn-dependent 
enzymes. Each particular amide hydrolysis enzyme targets a specific type of amide bonds. For 
example, carboxypeptidase hydrolyzes the C-terminus in a peptide residue, collagenase 
hydrolyzes collagen, dipeptidase hydrolyzes dipeptides and Histone Deacetylase (HDAC) 
hydrolyzes an acetamide group of a lysine residue on a Histone protein (Figure 1.2).
9 
One 
approach to the development of cancer drugs is targeting the enzymes that allow the uncontrolled 
replication of cancer cells. Histone deacetylase enzymes (HDAC) are one class of these targeted 
enzymes. Inhibiting these enzymes prevents the remove of the acetyl groups on N-acetyl lysine 
residues in histone proteins.
10
 Deacetylation plays an important role in many gene regulations, 
especially regulation of gene transcription. Histone components are present in the core of 
chromatin in DNA, and they control transcription and play an essential role in gene regulation. 
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Figure 1.2. The deacetylation by HDACs of the acetyl group from lysine in the presence of 
water, releasing an acetate molecule.   
 
The nucleosome is the fundamental unit of chromatin and it is composed of an octamer of 
the four core histones (H3, H4, H2A, H2B) around which 147 base pairs of DNA are wrapped 
(Figure1.3).
11
 The histone is important for establishing different ionic interactions between 
nucleosomes in chromatin. Therefore, chromatin can adopt different structural conformation 
depending on modifications that occur in the histone tails, specifically H-3 and H-4, which are 
targeted for various post-translational modifications such as acetylation, N-methylation, or 
phosphorylation.
12
 The mechanism of gene-transcription includes neutralizing the positive 
charge of histone lysine residues in order to result in more relaxed chromatin. Deacetylation of 
histone lysine residues increases ionic interactions between positively charged histones and 
negatively charged DNA, resulting in condensed chromatin and limiting gene transcription. 
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Figure 1.3. The nucleosome is the basic unit of chromatin and it consists of DNA wrapped 
around a histone octamer.
2 
 
Histone deacetylases comprise a family of 18 enzymes, which are grouped into classes I–
IV based on their homology to their respective yeast orthologues. Classes I, II and IV contain 11 
family members, which are referred to as classical HDACs; the other 7 members are in class III 
which are called sirtuins. Studies have shown that the classical HDACs are promising targets for 
anti-cancer drugs.
12 
Inhibition of HDACs can be used as a therapeutic approach to prevent 
deacetylation thus prevent cancer cells from replicating genes, and eventually killing them. 
Classes (I\II) show effective targets toward inhibiting cancer cells. In these two classes, a wide 
range of HDAC enzymes share the same structural characterization, which comprise of a zinc 
active site at the bottom of a tubular pocket.  
In HDAC, zinc is coordinated by two His residues and an aspartate residue as well as a 
water/hydroxide. It has been well recognized that certain histone deacetylase enzymes inhibitors 
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(HDACI) are promising cancer therapeutic agents.
10,12,13
 These inhibitors act by binding the 
HDAC, thus modifying gene expression to restore the normal differentiation or kill the programs 
of transformed cells. Several HDACIs have been isolated as natural or synthesized products. 
HDACs have been classified into 3 classes (I\II) NAD- dependent and class (III) (HDAC) 
Histone deacetylase enzyme. One example of a good HDAC inhibitor is suberanilohydroxamic 
acid (SAHA, also known as Vorinostat), which contains a zinc-binding group connected to an 
aliphatic chain and a capping group (Fig. 1.4).
14,15
 These three general components can also been 
found in several other HDACIs.  
 
Figure 1.4. The Structure of Vorinostat (SAHA) and the general structure of HDACIs. 
Three general regions that many HDACIs are comprised of: a cap, an aliphatic chain, and a zinc-
binding group. 
Vorinostat (SAHA) was the first drug approved by the FDA as a treatment for cutaneous 
T-cell lymphoma and is an effective HDACI.
13
 In addition to targeting cancer cells, HDACIs 
including SAHA have been identified as potential treatments of metabolic diseases, 
inflammatory diseases, neurodegenerative disorders, and cardiovascular disease. Another 
inhibitor used in this study was 8-Hydroxyquinoline (8HQ) (Figure 1.5). 8HQ is a 
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monohydroxyquinoline compound, which are found in plants and have a variety of known 
synthetic variants. It is a well-known strong chelator of metal ions with the ability to bind Zinc. 
It is worth noting that 8HQ derivatives also have pharmacological application to a wide range of 
diseases, such as HIV, breast cancer, prostate cancer, and fungal infections.
9
  
 
Figure 1.5. The 8-Hydroxyquinoline (8HQ) structure. 
 
         Although some progress has been made to understand drug-zinc interactions, a better 
understanding of the specific interactions between the zinc active site and the drug molecules is 
needed in order to design better drugs to treat cancers and other disorders. However, it is very 
difficult to work with the native enzymes, as they are time-consuming and challenging to 
produce in large amounts. In addition, the large size of enzymes makes spectroscopic techniques 
that target the active site difficult to perform and interpret. Instead, we chose to attempt to mimic 
the active site of the zinc enzymes by synthesizing small zinc-containing molecules that are 
models of the active site structures. Mimicking the structural and the functional properties of Zn 
enzymes will allow us to understand the binding reactivity between Zn
2+
 and its inhibitors and 
that new understanding will lead us to develop new techniques to deliver inhibitors or drugs to 
cancer cells. A variety of zinc complexes and their interactions with inhibitors such as SAHA 
and 8HQ have been studied.
1-4,6,10-13
 Previously, the interactions between zinc and various 
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ligands and inhibitors were examined in solution using isothermal titration calorimetry (ITC) in 
Dr. Jin’s lab in collaboration with Dr. Karver and Dr. Grice.16 
 In this work, several attempts were made to mimic the structure of Zn
2+
 metalloenzyme 
active sites shown in Figure 1.6 using complementary techniques to ITC to obtain more 
information. We explored different supporting ligands to examine the active site structures 
including methylamino-N,N-bis(2-methylene-4.6-di-tert-butylphenolato) (H2L1), bis(2-picolyl) 
amine (BPA, L2), hydrotris(3-phenyl-5-methylpyrazol-1-yl) (Tp
Ph,Me
, L3), and a similar neutral 
ligand (L4) (Figure 1.6). in previous work, complexes of BPA and Tp
Ph,Me 
have been examined 
for mimicking zinc active sites.
13,16
 In addition, the x-ray structures of Zn(L2) and  Zn(L3) 
complexes are known.
13,16,17
 The zinc complexes of these ligands were synthesized and then used 
in further studies (Figure 1.7). Given the small size of these complexes relative to the actual 
enzyme, we were able to study the interaction of enzyme inhibitors with the zinc center and also 
to characterize the functional properties of the mimicked structure by attempting to cleave a 
model amide group. More importantly, we studied the interaction of Zn
2+
-ligands towards 
inhibitors of histone deacetylase, such as Vorinostat (SAHA) and 8-hydroxyquinoline (8HQ). 
The results of this study are reported in the following chapters. Chapter 2 reports the 
experimental details of the studies. Chapter 3 reported the studies of the interaction between Zn
2+
 
and the ligands in Figure 1.6, and the functionality of these complexes (Figure 1.7). Chapter 3 
also studies of the interaction of inhibitors with the Zn
2+
-ligand binary complexes that had been 
previously identified as potential HDAC structural mimetics. Lastly, chapter 4 reports the 
interaction between Zn
2+ 
and ligands and between Zn
2+ 
and inhibitors using UV-Vis and 
fluorescence spectroscopies. 
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Figure 1. 6. Ligands explored in this work. On the top right is a benzyl-stubstituted 
bis(phenolato)amine (H2L1), L2 is bis(2-picolyl)amine (BPA), L3 is hydrotris(3-phenyl-5-
methylpyrazol-1-yl) (Tp
Ph,Me
), and L4. The atoms that can bind to metals are highlighted in blue.  
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Figure 1.7. Zinc Complexes of Ligands L1, L2, L3 and L4. The image shows the general 
expected bonding patterns for these complexes. L and X refer to generic neutral and anionic 
ligands, respectively.  
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Chapter 2. Experimental methods 
 2.1. General considerations  
All reactions and processes were carried out on the benchtop in the presence of air unless 
otherwise noted. Zn[N(TMS)2]2 was purchased from Sigma Aldrich, and BPA ( ˃ 98.5%) was 
purchased from TCI. All other reagents and solvents were purchased from commercial suppliers 
and used as supplied. All NMR spectra were collected using a Bruker Avance 300 MHz NMR 
spectrometer at 298 K. 
1
H NMR spectra were referenced against residual solvent peaks and 
reported downfield of tetramethylsilane (δ = 0 ppm). UV–Visible (UV–Vis) spectra were 
obtained with a Varian Cary 100 UV–Vis spectrometer. Infrared (IR) spectra were collected on 
an ABB FTLA2000 IR spectrometer equipped with a PIKE Technologies MIRacle diamond 
ATR (attenuated total reflectance) anvil. Fluorescence spectra were obtained with a Varian Cary 
Fluorescence spectrophotometer.  
2.2. Preparation of the Ligands, Zn-ligands, and reactions of (ZnL) with inhibitors 
2.2.1. Synthesis of H2L1 
The methylamino-N,N-bis(2-methylene-4.6-di-tert-butylphenolato) (H2L1) was 
synthesized in two steps based on a modification of the procedure by Silvernail C. and co-
workers. A solution of methylamine (7.5 ml, 0.2 mol) was added dropwise at 0 °C to a stirring 
solution of paraformaldehyde (5.2 g, 0.2 mol) and KOH (0.01 g, 0.2 mol) in 25 ml of ethanol.  
After the mixture was allowed to warm to room temperature, a second solution of 2,4-di-tert-
butylphenol (35.5 g, 0.2 mol) in 25 ml ethanol was added to the first mixture in one portion. The 
reaction was heated to reflux for 24 h. After allowing the reaction to cool, the solvent was 
removed under vacuum, and the product was rinsed with 20 mL of ethanol. The final product 
was a white solid (2.11 g, 3.4%). NMR data matched literature values.
3
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2.2.2. Synthesis of [Zn(L1)]2 
[Zn(L1)]2 was prepared by adding Zn[N(TMS)2]2 (0.3 ml, 5.7 mmol, TMS = 
trimethylsilyl) to a stirring solution of H2L1 (70 mg, 5.7 mmol) in 5 ml toluene. The green 
mixture was stirred at room temperature for 16 h. A light green powder (0.03 mg, 43%) was 
obtained after washing the product with 5 ml pentane. 
1
H NMR (300 MHz, CD2Cl2): δ = 5.32 (s, 
2H), 7.30 (s, 2H, PhH), 7.09 (s, 2H, PhH), 7.02 (s, 2H, PhH), 6.70 (s, 2H, PhH), 4.98 (d, J) 13 
Hz, 2H, CH2), 3.90 (d, J) 13 Hz, 2H, CH2), 3.40 (d, J) 13 Hz, 2H, CH2), 2.57 (d, J ) 13 Hz, 2H, 
CH2), 1.39 (s, 18H, t Bu), 1.29 (s, 18H, t Bu), 1.20 (s, 18H, t Bu), 1.18 (s, 18H, t Bu).
 
 
2.2.3. Reaction of [Zn(L1)]2 with suberanilohydroxamic acid (SAHA)  
[Zn(L1)]2 (0.3 g, 0.02
 
mmol) and SAHA (6.5 g, 0.02
 
mol) were dissolved in 10 ml 
acetonitrile. The reaction was stirred for 24 h in a 60 °C oil bath, and then the solvent was 
removed under vacuum. Crystallization was attempted using vapor diffusion by dissolving the 
product in methanol and placing the vial in a larger vial filled with pentane. The product did not 
crystallize, therefore the solvent was removed under vaccum and the mass of the solid was 
obtained (44.1 mg, 86.5%).  IR and 
1
H NMR spectra are shown in chapter 4.  
2.2.4. Reaction of [Zn(L1)]2 with 8-hydroxyquinoline (8HQ) 
[Zn(L1)]2 (50 mg, 0.04
 
mmol) and 8HQ (5.9 mg, 0.04 mmol) were dissolved in 5 ml 
acetonitrile. As soon as 8HQ was added, the color of the mixture turned to yellow. The reaction 
was stirred for 24 h in a 60 °C oil bath.  The product was then dried using a rotary evaporator, 
resulting in a yellow power with a 0.05 g yield (85.7%). 
1
H NMR spectra are shown in chapter 4.  
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2.2.5. Synthesis of Zn(L2)Cl2 
A sample of commercially purchased bis(2-picolyl)amine (BPA, L2) (0.25 ml, 0.1 mmol) 
was added to stirring solution of (17 mg, 0.1 mmol) of zinc dichloride and 5 ml methanol. The 
reaction as heated at 60 
º
C for 24 h. The product was filtered and dried. Spectral data matched 
literature values.
16 
2.2.6. Reaction of Zn(L2)Cl2 with 8HQ 
A sample of Zn(BPA)Cl2 (0.8 mg, 3.4 mmol) and 0.5 mg (3.4 mmol) of 8HQ were 
dissolved in 5 ml acetonitrile (ACN). The reaction was stirred in 60 
º
C oil bath for 48 h. the 
1
H 
NMR spectra are shown in chapter 4.  
2.2.7. Previous syntheses of Zn(L3)OH, Zn(L3)(8HQ), and L4 
 Zn(L3)OH
 
and Zn(L3)(8HQ)
 
were previously prepared in Dr. Grice’s lab by other 
researchers.
13 
The ligand L4 was prepared by Mark Gudger in the Grice lab and characterized by 
1
H and 
13
C{
1
H} NMR as well as X-ray crystallography and elemental analysis (unreported data).  
2.3. Other experimental details 
2.3.1. Attempted synthesis of a benzylated version of H2L1
 
An attempt was made to synthesize a benzylated version of H2L1, benzylamino-N,N-
bis(2-methylene-4.6-di-tert-butylphenolato). A solution of benzylamine (9.45 ml, 0.1 mol) was 
added dropwise at 0 ˚C to a stirring solution of paraformaldehyde (5.2 g, 0.2 mol) and KOH 
(0.077 g, 1.2 mmol) in 25 ml of ethanol.  After the mixture was warmed to room temperature, a 
second solution of 2,4-ditertbutylphenol (35.5 g, 0.2 mol) in 25 ml ethanol was added to the first 
mixture in one portion and the reaction was heated to reflux for 24 h. After allowing the reaction 
to cool, the solvent was removed under vacuum, and the product was rinsed with 20 mL of 
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ethanol. The final product was a white solid (18.8 g, 89.9%). 
1
H NMR (300 MHz, CDCl3): δ = 
7.20 (m, 5 H, Ar), 7.07 (d, JHH = 2.80 Hz, 1H, Ar), 6.67 (d, JHH = 2.21 Hz, 1 H, Ar), 4.71 (s, 2 H, 
NCH2O), 3.90 (s, 9 H, ArCH2N), 3.80 (s,2 H, CH2Ph), 1.70 ((s, 2, C(CH3)3), 1.30 ((s, 2, 
C(CH3)3) ppm.
18
 When comparing these spectra with the spectra for H2L1, it showed different 
signals than would be expected for the desired product. Therefore, the final product is not of the 
fomula H2L, but rather using benzylamine as a starting material yielded a benzoxazine product 
(Scheme 2.3.1).  
Scheme 2.1. Benzoxazine synthesis. This reaction occurred during instead of the desired ONO 
ligand (a derivative of H2L1).  
2.3.2. Alternative synthesis of [Zn(L1)]2 
An alternative approach was performed by using a different Zn-containing species as a 
starting material. Zn(OAc)2·2H2O (21 mg, 0.1 mmol) was added to a stirring solution of (70 mg, 
0.1 mmol) (H2L1) and 5 mL toluene. The reaction was stirred for 14 h at ambient temperature. 
Then, the solvent was evaporated to dryness on rotary vaporator and a light green solid was 
formed. 
1
H NMR (300 MHz, CDCl3): 7.24 (s, 2H, PhH), 7.23 (s, 2H, PhH), 7.18 (s, 2H, PhH), 
7.16 (s, 2H, PhH), 4.86 (s, 2H, CH2), 4.63 (s, 2H, CH2), 3.64 (s, 2H, H2O), 3.45 (s, 2H,CH2), 
2.33 (d,J 13 Hz, 2H, CH2), 2.11 (s, 3H, CH3), 12.03 (s,18H, tBu), 1.40 (s, 18H, tBu), 1.28 (s, 
18H, tBu), 1.25 (s, 18H, tBu). 
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2.3.3. Reaction of [Zn(L1)]2 with SAHA and base 
Suberanilohydroxamic acid (10.8 mg, 0.4 mmol), a sample of KOH (2.3 mg, 0.04 mmol) 
and 18-crown-6 (10 mg, 0.03 mmol) were added to 7 ml methanol. The reaction was allowed to 
stir until complete dissolution. Next, 50 mg (0.04 mmol) of [Zn(L1)]2 was added to the reaction, 
then it was allowed to stir at room temperature for 24 h. The solution was evaporated to dryness 
on a rotary vaporator, and a white solid was recrystallized from tetrahydrofuran (2 ml). However, 
the solid did not precipitate and therefore the solvent was removed. 
1
H NMR spectra was taken, 
and showed tert-butyl signals at the shifts of δ = 1.39 (s, 18H, tBu), 1.29 (s, 18H, tBu), 1.20 (s, 
18H, tBu), 1.18 (s, 18H, tBu). 
2.3.4. Attempted deprotonation of SAHA 
  Suberanilohydroxamic acid (SAHA) (0.2 g, 0.7 mmol) was added to 5 ml methanol. In 
the same mixture, 18-crown-6 (0.2 g, 0.7 mmol) and KOH (0.04 g, 0.7 mmol) were added. The 
reaction was allowed to stir at room temperature for 3 h. the solution was evaporated to dryness 
on a rotary vaporator. The resulting compound was a clear oil. 
1
H NMR (300 MHz, CDCl3) δ = 
7.72 (d, 2H), 7.03 (t, 1H), 2.37 (t, 2H), 2.19 (t, 2H), 2.00 (s, 1H), 1.87 (d, 1H), 1.74 (t, 2H), 1.64 
(t, 2H), 1.40 (s, 2H). THF (2 ml) was added; however, the solid only partially dissolved. 
Therefore, the mixture was separated by glass wool into a solid and a solution. The solid was 
recrystallized in THF by allowing pentane to vapor diffuse into the solution. However, a yellow 
semi-crystalline viscous material was produced instead of crystals. The solution was evaporated 
to dryness and the residue was dissolved in methanol. Pentane was allowed to vapor diffuse into 
methanol. Small particles were observed and the product was washing four times with THF to 
yield a white solid (1.6 mg, 0.4%). The characteristic IR peaks for (O-H) and (N-H) in SAHA 
are: 3286, 3251 and 3137 cm
-1
. As in this range, it was hard to differentiate the (O-H) bands 
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from the (N-H) bands. In comparison, the IR spectra for deprotonated SAHA shows one band at 
3306 cm
-1
. The lack of the broad band in the same region indicates that SAHA might be 
protonated. T 
1
H NMR showed that this material matched SAHA, and the IR spectra displayed a 
broad band for (O-H) that differed from SAHA’s IR spectra and the deprotonated IR spectra. 
Together, this indicates that deprotonation did not occur. 
2.3.5. Reaction of [Zn(L1)]2 with 8HQ 
 A sample (31 mg, 0.05 mmol) of [Zn(L1)]2 was added to 5 ml chloroform-d. In the same 
solution, 8.3 mg (0.05 mmol) of 8HQ, 0.31 mg (0.05 mmol) of KOH, and 15 mg (0.05 mmol) of 
18-crown-6 were added. The reaction stirred for 24 h in ambient temperature. The solution was 
evaporated to dryness. 
2.4. Attempted hydrolysis of amide bonds 
 Several Zn-ligand complexes were examined as catalysts to hydrolyze a secondary amide 
bond in a small molecule substrate. The general procedure was as follows: 1 equivalent of Zn-
ligand species and one equivalent of N-benzylacetamide (the substrate) were dissolved in 
dimethyl sulfoxide-d6 (DMSO-d6) and water (1:1 solution). The mixture was heated and stirred 
in an oil bath at 100 °C for a long period of time (several days). 
1
H NMR spectra were collected 
for each reaction and are shown in Chapter 3. The
1
H NMR spectra of benzylamine and N-
phenylacetamide were taken to compare with the spectra of the reactions of each ZnL. 
1
H NMR 
(300 MHz, DMSO) for benzylamine: δ =7.21-7.37 (s, 5 H, Ph), 3.87 (s, 2H, CH2) and 1.41 (s, 
2H, NH2). 
1
H NMR for N-phenylacetamide (300 MHz, DMSO) δ = 7.31 (s, H, NH), 7.29 (s, 2H, 
Ph), 7.25 (s, 2H, Ph), 7.23(s, H, Ph), 4.25-4.23 (d, 2H, CH2), 1.86 (s, 3H, CH3). 
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2.5. UV-Vis analysis of the interaction between Zn
2+
, Ligands and inhibitors    
 Different concentrations of Zn-ligand complexes were dissolved in 5 ml acetonitrile 
(ACN). We attempted this process for all ZnL species reported in this thesis. The Varian UV 
Scan software was used to collect the data. Quartz cuvettes were used in order to avoid 
dissolving plastic cuvettes with organic solvents. In addition, different concentrations of 
Zn(L2)Cl2 were dissolved in 5 ml buffer solution (50 mM NEM, 0.15 M NaCl, pH 6.8). After 
taking the spectra of Zn-ligand complexes, a fixed amount of ZnCl2 (7 mg) was added to the 
measured solution of Zn-ligand.  Then, the spectra of (ZnL) and the additional ZnCl2 was taken. 
Spectra are shown in chapter 4 section 4.1.  
2.6. Fluorescence analysis of the interaction between Zn, ligands and inhibitors    
 The maximum fluorescence emission wavelengths of Zn-ligands and inhibitors were 
collected using excitation wavelengths at 240 nm, 260 nm and 310 nm. We used these 
wavelengths to determine the emission spectra of each Zn-ligand-inhibitors species.  The 
software used was Cary Eclipse Scan. The general procedure involved using a small amount of 
Zn-ligand (ca. 1 mg) and inhibitor dissolved in 5 ml acetonitrile. Spectra are shown in chapter 4.      
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s oep h ni ht3p  CtC ar tt3  Ce  t C o3e p  th t3p ho pta3 ttp  t3 tetpahC, o3e assessment of 
  tehattCtC o ptrtpt 
The focus of this project was to form mimetic complexes of the HDAC active site and 
study their interactions with different HDAC inhibitors. The design of the Zn-ligand complexes 
must obey certain requirements to be qualified as mimicking zinc enzymes active sites. Previous 
ITC studies of the interaction of Zn
2+_
with several ligands indicate that for a successful mimetic, 
the ligand must strongly chelate to Zn
2+
, form a complex with a zinc-to-ligand ratio of 1:1, and 
still have open coordination sites for the inhibitor to interact.
16
  Zn
2+
 coordination complexes can 
exist in solution with tetrahedral, trigonal bipyramidal, or octahedral geometries. The tetrahedral 
and trigonal bipyramidal geometries are particularly preferred by Zn
2+
, and provide only four or 
five total coordination sites, respectively. Therefore, using tetradentate or pentadentate ligands to 
form the zinc:ligand complex leads to insufficient coordination sites left on Zn
2+
 for the inhibitor 
binding.
16
 Both inhibitors used in this study are bidentate chelating ligands, which makes them 
good inhibitors to bind metals in enzyme active sites because their coordination will be stabilized 
by the chelate effect. In this chapter the synthesis of zinc enzyme active site mimics are reported 
along with their interaction with enzyme inhibitors, as studied by NMR spectroscopy. The ability 
of the zinc complexes to act as functional mimics of HDAC is also explored. Finally, 
computational calculations were performed to optimized Zn(L1) and Zn(L1)(AHA) structures. 
3.1. Ligands with O, N, O coordination framework
 
3.1.1. Synthesis of H2L1 and its zinc binary complex 
 
Given that the coordination geometry of the HDAC active site contains two aspartates 
and a histidine residue, we sought to mimic this with a tridentate ligand with one nitrogen and 
two oxygen donors. Methylamino-N,N-bis(2-methylene-4,6-di-tert-butylphenol (H2L1) is a 
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tridentate ligand that can bind to transition metal ions such as Zn
2+ 
(Figure 1.6). The [Zn(L1)]2 
complex was studied by Silvernail C. M. and co-workers using 
1
H NMR, 
13
C NMR spectroscopy 
and X-ray crystallography.
3
 H2L1 was prepared by a condensation of methylamine, 
paraformaldehyde and tert-butylphenol in refluxing methanol. Then, the addition of 
Zn[N(TMS)2]2 resulted in a dimeric complex, [Zn(L1)]2. In the solid state, the complex 
possesses a dinuclear structure with each Zn
2+
 ion coordinating two oxygens and one nitrogen of 
each bis-phenolate amine and coordinating to an oxygen of a second molecule of the Zn(L1) 
monomer. However, it has been reported that in solution such as tetrahydrofuran-d8, this dimeric 
compound is in equilibrium with a monomeric solvent-bound structure (Scheme 3.2). In addition 
to following the reported synthesis, we found that the specialized reagent Zn[N(TMS)2]2 was not 
necessary for synthesis of [Zn(L1)]2. The cheaper and less sensitive salt Zn(OAc)2·2H2O was 
equally effective in reaction with H2L1.  
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Scheme 3.1. Synthesis of methylamino-N,N-bis(2-methylene-4,6-di-tert-butylphenol (H2L1) 
and its reaction with a Zn
2+ 
source.  
 
 
 
Scheme 3.2. The equilibrium equation between the dimeric complex [Zn(L1)]2 and the 
monomeric complex in the presence of a donor ligand.  
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3.1.2. Attempted synthesis of a benzylated version of H2L1. 
 We attempted to synthesize a variant of H2L1 by using benzylamine instead of 
methylamine. Unfortunately, the desired ligand was not produced. Instead, a cyclic benzoxazine 
was formed (see section 2.2.1).  It was surprising that such a minor modification of the starting 
material led to such a different product.  
3.1.3. Synthesis of a bis(2-picolyl)amine (BPA) complex of Zn
2+ 
Commercially available bis(2-picolyl)amine (BPA, L2) was also studied as a potential 
ligand to develop an zinc-enzyme active site  structural and functional mimetic. BPA has been 
identified as a promising ligand in ITC studies. BPA is a tridentate ligand that can potentially 
bind Zn
2+
 with two pyridine nitrogen atoms and the nitrogen of the secondary amine. The 
Zn(BPA)Cl2 was synthesized at 60 °C using commercially purchased bis(2-picolyl)amine and 
zinc dichloride dissolved in methanol. The product was isolated and was confirmed as 
Zn(BPA)Cl2 by obtaining spectral data that matched literature values.
16
 Zn(L2)Cl2 is well known 
and its crystal structure has been reported.
17
 No evidence was observed for other binding modes 
of BPA (such as a 2:1 BPA:Zn ratio) in the sample of Zn(L2)Cl2 that was synthesized and used 
in the studies.  
 
Scheme 3.3. The reaction of the tridentate bis(2-picolyl)amine (BPA) and ZnCl2. 
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3.1.4. Previously synthesized (ZnL) Species 
 Zn(Tp
Ph,Me
)OH and Zn(Tp
Ph,Me
)(8HQ) have been previously reported in the Dr. Grice 
group and were used in this study.
13
 In addition, a previously unreported ligand (L4) and its zinc 
complex were also examined. L4 was synthesized by Mark Gudger in the Grice lab according to 
the following reaction and has been characterized by 
1
H NMR, elemental analysis and X-ray 
crystallography (unreported data).  
 
Scheme 3.4. The synthesis reaction of L4. The nitrogen atoms in blue in L4 are the donors 
in the ligand that coordinate to Zn
2+
. 
 
3.2. Examining the hydrolytic activity of Zn-ligand complexes 
 The amide bond is ubiquitous in nature. They are the key chemical linkages in peptides 
such as proteins, enzymes, and antibodies. The resonance structures of amides explain many of 
the properties of this functional group, such as the short (N−C(O)) bond length, barrier to 
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N−C(O) rotation, planar geometry, IR stretching frequencies, 13C NMR chemical shifts, and 
resistance toward nucleophilic attack.
19
 Most biological reactions are catalyzed by enzymes, 
including hydrolysis of proteins, fats and carbohydrates. Although amides can readily be cleaved 
by enzymes such as proteases, it is difficult to selectively break the carbon–nitrogen bond of an 
amide using standard organic chemistry.
20
 Transition-metal-catalyzed cleavage of inert chemical 
bonds such as C−H, C−C, and C−O bonds is an important area of organic chemistry and 
organometallic chemistry.  
The cleavage of amide C−N bonds, especially by transition-metals, was initially reported 
in 1980, and has become an area of focus since 2010. It provides a mild and convenient approach 
to obtain nitrogen and/or carbon sources for the synthesis of valuable products.
21
 Here we 
attempted to determine if amide carbon–nitrogen bonds can be activated and cleaved using 
ligand-Zn
2+
 binary complexes that had been identified as potential HDAC structural mimics. We 
wished to determine if the Zn-ligand complexes have the ability to function as an enzyme. 
Transition-metal-catalyzed C−N bond cleavage is classified into five approaches: (1) via 
oxidative addition of transition-metal catalysts to C−N bond, (2) via imine or iminium species, 
(3) via ammonium species, (4) via β-amino elimination, and (5) via insertion/deinsertion.21 Two 
types of C−N bonds, including the amide C−N bond and the non-carbonyl C−N bond, are 
involved in an amide molecule. Generally, the amide C−N bond is considered to be more 
reactive than the non-carbonyl C−N bond. Another factor to consider in this process is sterics. 
An amide bond that is less sterically hindered by substituents is more likely to be cleaved.
22
 In 
Scheme 3.5 the mechanism of hydrolyzing an amide bond by a Zn-ligand complex with a bound 
hydroxide is shown.  
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Scheme 3.5. The mechanism of hydrolyzing an amide bond by a Lewis acidic Zn
2+
.  
 
We used N-benzylacetamide as a model for the substrate of Histone Deacetylase. The 
hydrolysis of benzylacetamide was not successful at room temperature. Therefore, the reaction 
was performed in an 100 
º
C oil bath with a variety of catalysts. The 
1
H NMR spectra of the 
solutions were collected at different times of the reaction (Scheme 3.6).  
 
Scheme 3.6. The hydrolysis reaction of benzylacetamide in the presence of H2O and 
catalysts (ZnL) with heat.  
In order to determine whether the reaction between Zn-ligand and amide compound 
occurred, the 
1
H NMR spectra for the amide starting material and benzylamine were taken as 
reference spectra. We examined the hydrolysis of benzylacetamide using four Zn-ligand 
complexes, ZnCl2 and an Al
3+
 compounds in a 1:1 mixture of water and DMSO-d6 (for solubility 
and NMR locking purposes). The data is shown in Table 3.1.
 
 
 
34 
Table 3.1. Hydrolysis attempts for benzylacetamide in the presence of various catalysts. 
Complexes Temperature (°C) Time  Result  
Zn(L1)
 60-100 >2 weeks  No hydrolysis  
Zn(L2)
 100 > 3 weeks  No hydrolysis 
Zn(L3)
 100 > 3 weeks No hydrolysis 
ZnCl2 100 > 3 weeks No hydrolysis 
Zn(L4) 100 > 3 weeks No hydrolysis 
Al(NO3)3·9H2O 
 100 > 3 weeks Some hydrolysis 
 
Unfortunately, none of the zinc complexes tested showed clear evidence for C−N bond 
cleavage under the reaction conditions studied. Using Al
3+
 in the form of aluminum nitrate 
nonahydrate, Al(NO3)3·9H2O, some hydrolysis was observed after extended heating in pure D2O, 
rather than a mixture of DMSO and water. These results highlight the stability of amide bonds 
and show that while the zinc complexes studied in this work may be structural models for the 
enzymes of interest, they are not functional mimics of hydrolase enzymes. Although the identity 
of the atoms in the 1
st
 coordination sphere are the same or similar as in HDAC and other 
hydrolyase enzymes, the exact positioning of these atoms are most likely not the same. In 
addition, though Zn
2+ 
is important to catalysis, the enzyme catalytic active site provides catalytic 
amino acid residues positioned in ideal locations to interact with the substrate and lower 
transition states through acid-base interactions. In our complexes, these additional residues are 
not present, so the substrate has to compete with other ligands to bind to the metal and likely has 
much higher reaction barriers to overcome. These are major reasons why trying to mimic 
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enzyme active sites with small molecules is so challenging
9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Figure 3.1. 
1
H NMR spectra of the hydrolysis reaction mixture of amide substrate and 
Zn(L2) in DMSO, in the presence of water and heat. Spectrum in black was collected after 24 
h and the spectrum in red was collected after 3 days in an oil bath (100 ºC). Comparing these 
spectra with the spectrum of benzylamine, it appeared that there was no sign of amine formation. 
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9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Figure 3.2. The 
1
H NMR spectra monitoring the hydrolysis of amide substrate with 
Zn(L3)OH in DMSO, in the presence of water and heat. The spectrum in black was collected 
after 24 h and the spectrum in red was collected after 3 days in an oil bath (100 ºC). Comparing 
these spectra with the spectrum of benzylamine, it appeared that there is no sign of amine 
formation. 
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Chemical Shift (ppm)
Figure 3.3. The 
1
H NMR spectra for the reaction of ZnCl2 and amide complex in the 
presence of water and heat. The lower spectrum in black was taken at 24 h, and the above 
spectrum in red was taken after 3 days in the oil bath. As shown, no evidence of amine product is 
present. 
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Chemical Shift (ppm)
 
Figure 3.4. 
1
H NMR spectra monitoring the reaction of Al(NO3)3·9H2O with amide in 
presence of water and heat. The mixture was dissolved in D2O (deuterium oxide). Heat was 
applied to the reaction with an oil bath (100 ºC) and the spectrum in black was taken of the 
reaction after 22 h. The spectrum in red was taken of the reaction after approximately one month. 
The appearance of benyzlamine was observed, but complete hydrolysis did not occur even after a 
month of heating. 
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 3.3. Studies of interaction of Zn2+-ligand complexes with inhibitors 
3.3.1. Zn(L1) with Vorinostat (SAHA) 
Many HDACIs share the same pharmacophore structure shown in Figure 1.4, which 
consists of a zinc binding group (ZBG) that chelates the zinc ion, a capping group that caps the 
active site binding pocket, and a linker between the ZBG and the cap. One ZBG of interest is the 
hydroxamic acid functional group present in SAHA, because of its significant binding ability to 
zinc ions. However, inhibitors with these coordinating groups can cause  severe toxicity due to 
their nonspecific chelation to metals.
23,24
 Other HDACIs have been discovered that are far more 
potent than SAHA, but are also typically more toxic as revealed in in vivo studies.
25 
SAHA is one 
of the most commonly used HDACIs, targeting multiple HDAC enzymes, which makes it 
difficult to determine if the therapeutic function and the toxicity of SAHA is a result of non-
specific binding to biological metals or to inhibiting a specific HDAC or a multiple HDACs.
26
  
 
Figure 3.5. The interaction between Zn
2+
 in HDAC and the hydroxamic acid group in 
SAHA. The ligand with the R group is SAHA, and the two histidine and asparagine groups are 
residues in the HDAC active site coordinating to the hydrolytically active Zn
2+
 ion. 
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By using computational chemistry (DFT and QM\MM calculations), Chen and co-
workers studied the binding of various HDAC inhibitors and Zn
2+
.
27
 The results showed that the 
hydroxamate group has a pKa of 9.4 in solution, and that the aliphatic linker has the ability to 
form van der Waals interactions with the pocket.
14
 When performing experiments with the goal 
of forming Zn(L1)(SAHA), we considered several approaches and analyzed the products via 
1
H 
NMR, UV-Vis, IR and fluorescence spectroscopies.  The first approach was to deprotonate 
SAHA by adding 1 equivalent of base (KOH and 18-crown-6), and then add 1 equivalent of 
[Zn(L1)]2 in methanol.  The reaction was stirred for 24 hours, but no Zn−SAHA product was 
formed, as determined by IR and 
1
H NMR
 
spectra. The second approach was to dissolve 1 
equivalent of [Zn(L1)]2 and 1 equivalent of SAHA in acetonitrile and heat the reaction at 60 ˚C 
for 24 h. There was some shifting in the 
1
H NMR spectra, but no clear evidence of product 
formation.  Therefore, the final approach was to elevate the temperature of the oil bath to 100 ˚C 
for the same reaction.  A white solid was formed, and a 
1
H NMR spectrum was taken.  Although 
there was change in 
1
H NMR spectra, the overlapping between the signals of the ligand and the 
inhibitor made it hard to determine if Zn binding with SAHA has occurred.   
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Chemical Shift (ppm)
 
Figure 3.6. 
1
H NMR spectra of Zn(L1) and SAHA at 60 ˚C for 24 h. The spectrum in black is 
for the Zn(L1)
 
with SAHA before heating. The spectrum in red is for the Zn(L1) with SAHA 
after 40 h under 60 ºC. As indicated before, spectral changes occurred, but the overlapping 
between signals in the spectra makes it hard to identify the binding between the Zn
2+
 and SAHA. 
 
3.3.2. Zn-Ligand interaction with 8-hydroxyquinoline (8HQ) 
8-hydroxyquinoline is a well-known strong metal ion chelator with a rich diversity of 
biological properties that has been shown to be an inhibitor of HDAC2. 8-Hydroxyquinoline 
binds Zn
2+
 through the phenolic oxygen anion and the pyridinic nitrogen (Figure 3.7).  
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Figure 3.7.  8-HQ interaction with Zn
2+
 in an HDAC Active Site. 
Reaction between Zn(L1)
 
and 8HQ was studied by combining them at 60 ˚C. 1H NMR 
spectra were collected (Figure 3.8), and as shown in the spectra, a broad signal appeared at 2.23 
ppm, corresponding to water formation with no other major changes observed. The color of the 
solution changed to yellow, indicating that 8HQ was reacting. However, 
1
H NMR spectroscopy 
did not reveal clear evidence of 8HQ coordinating to the zinc complex. The signals for the 8HQ 
and the Zn(L1) did not shift appreciably enough to make a clear conclusion.  
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Figure 3.8. 
1
H NMR spectra for Zn-L1 interaction with 8HQ in ACN. The black spectra 
were taken before heat was applied to the reaction, the red spectra for the reaction after 21 h in 
oil bath 60 ˚C, the blue spectra for the reaction after 3 days in oil bath and the green spectra was 
for the reaction after one week in oil bath. The mixture was yellow before heat applied and the 
color started to change gradually until it turned to orange.  
 
3.4. Computational studies of the interaction of AHA and Zn(L1) 
Ab initio calculations were performed with the Gaussian 2009 program package.
27
 Two 
zinc complexes were optimized using HF (Hartree-Fock) as well as DFT (Density Functional 
Theory) levels of theory with a B3LYP functional. Both approaches used a 3-21G basis set.
28
 
The zinc ion was first bound to the bis(phenolato)amine and methylamino-N,N-bis(2-methylene) 
as shown in Figure 3.9. These ligands are models for L1, but without the tert-butyl substituents 
in order to reduce computational time. Both complexes were successfully optimized in 
reasonable conformations.  Moreover, the optimized Zn-ligand complexes have at least one or 
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two open sites that could bind with the inhibitor, to form complexes with a tetrahedral or higher 
geometry.   
Bonding of the zinc complexes to an inhibitor was examined with deprotonated 
acetohydroxamic acid (AHA) as the inhibitor, a small molecule analog of SAHA. As with 
SAHA, AHA is a bidentate inhibitor that complexes the Zn
2+
 in the HDAC active site through 
both hydroxamate oxygen atoms. The binding modes that were optimized are shown in Fig 3.10, 
and the binding energy of each mode was found. The binding mode of the AHA anion in models 
A and D is mono-dentate, whereas in models B and C, the binding is bidentate. In Table 3.2, the 
basis set superposition error (BSSE) and the binding energies of Zn
2+
 and the ligand are reported. 
BSSE-corrected energies of all models differ in terms of the binding structures. In addition, 
Hartree–Fock calculations are known to underestimate the electron correlation in the molecule; 
thus, this method may provide incorrect numbers, but is useful to examine in terms of general 
trends between different complexes. Using HF, models A and D share the same bonding energy 
of 45.35 kcal/mol.  The highest binding energy that was calculated in the HF method is of model 
C. On the other hand, in the DFT/B3LYP method, model A has the highest energy 73.92 kcal/mol 
and the lowest number is model D with 45.85 kcal/mol. The DFT/B3LYP approach would be 
expected to be more accurate than HF, so these numbers are likely closer to the real values. The 
distances between Zn and O’s in models A, B and C are between 2 to 3 Å. It should be noted that 
models A and D have different distance between the metal and the O in the amide group. In most 
hydroxamate complexes characterized by X-ray crystallography, the metal-OC bond is longer 
than metal-ON bond. However, the magnitude of the difference is different among different 
metal complexes.
29
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Figure 3.9. Two different models of the Zn(L) species: Zn(2,2'[[(phenylmethyl)imino] 
bis(methylphenol)]) (Zn-L(Me) (1) and Zn (2,2'[[(methyl)imino]bis(methylphenol)] Zn-
L(Ph) (2). Both complexes shown were calculated in gas phase via HF level of theory with a 3-
21G basis set. Atoms are labeled by color, where red atoms are O, blue atoms are N, purple is the 
Zn
2+
, gray are C atoms, and white are H atoms.  
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Figure 3.10. Four different models of the Zn-Ligand-AHA species.  A) HF optimized 
structure, AHA C-O site bonding with Zn-L complex (1), B) HF optimized structure, AHA C-O 
site bonding with (ZnL) complex (2), c) HF optimized structure, AHA N-O site bonding with 
(ZnL) complex (1) and D) HF optimized structure, AHA C-O site bonding with (ZnL) complex 
(2). The DFT/B3LYP structures were similar, but with slightly different distances.   
Table 3.2. BSSE-corrected Binding Energies of Zn
2+
 and the ligand  
 Zn-L(Me) (1) 
kcal/mol 
Zn-L(Ph) (2) 
 kcal/mol 
HF/3-21G 213.49 213.47 
B3LYP/3-21G 126.07 131.75 
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Table 3.3. BSSE-corrected Binding Energies of Zn-Ligand complexes with  
 Model A 
kcal/mol 
Model B 
kcal/mol 
Model C 
kcal/mol 
Model D 
kcal/mol 
Chelating  Monodentate  Bidentate  Bidentate  Monodentate 
HF/3-21G 45.35 44.42 49.21 45.35 
B3LYP/3-21G 73.92 68.63 73.50 45.85 
 
Table 3.4. The distances between Zinc and the AHA oxygens.  
 
  
 
 
 
In conclusion, several structural mimetic complexes of HDAC were synthesized and 
characterized. These complexes were found not to be functional mimetics of HDAC because 
they show no activity towards hydrolyzing amide bonds. However, Al(NO3)3·9H2O was used as 
an alternative metal to hydrolyze amide bonds without the presence of a supporting multidentate 
ligand. The interaction of zinc complexes and inhibitors were examined by 
1
H NMR, but the 
spectra were hard to analyze due to the overlapping signals. This indicates that the 
1
H NMR is 
not an ideal choice of spectroscopy to study the interactions. As shown in the following chapter, 
UV-Vis and fluorescence spectrometry were found to be more promising. Finally, a 
computational study of Zn(L1) was performed by using two different approaches HF and 
 HF/3-21G  (Å) B3LYP/3-21G (Å) 
Zn-L AHA Zn-ON Zn-OC Zn-ON Zn-OC 
Model A 4.59 2.69 1.91 2.56 
Model B 2.82 1.99 2.11 1.99 
Model C 2.02 3.42 1.92 2.05 
Model D 4.59 1.97 4.662 1.95 
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DFT/B3LYP, both using the 3-21G basis set. Calculations were performed on the interaction 
between Zn-Ligand compounds and AHA. Four different models were optimized and their 
binding energies were determined. The computational data reveal that the inhibitor (AHA) binds 
the metal most favorably in a bidentate fashion. However, given the low basis set and the use a 
gas phase conditions, the numbers in this study cannot be directly compared to experimental 
information. The binding affinities of the ligands and inhibitor to Zn
2+
 need to be calculated by 
using more advanced methods (functional benchmarked for zinc complexes, larger basis sets, 
solvation models, etc.) to obtain values that can be directly comparable to experimental data.   
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Chapter 4. Examining the binding between Zn
+2
 and ligands and inhibitors using UV-Vis and 
fluorescence spectroscopies  
4.1. Determining the binding affinities between the Zn
2+
 and ligands and Zn-ligand complexes 
with inhibitors using UV-Vis spectroscopy 
4.1.1. Introduction  
UV-Vis spectroscopy is a common technique to monitor molecular interactions or 
chemical reactions.
 
In spectroscopically monitored titration experiments, the association constant 
(Ka) between a ligand and a metal ion can be determined from changes in the parameters of the 
spectra, such as wavelength of maximum absorbance (λmax) and molar absorptivity (ε).
 30 
Typically, a titration is performed by holding the concentration of one species constant (in our 
case the Zn-ligand complex), while increasing the concentration of the other species (Zn
2+
), 
keeping overall volume nearly the same. In our studies, we applied this concept to determine the 
association constant between Zn
2+
 and a ligand from the spectra after adding one aliquot of a 
Zn
2+
 source to a Zn-ligand complex in solution.  
The basis for this type of analysis is Beer’s Law, applied at the λmax of the absorption of 
the Zn-ligand complexes.  
Beer’s Law is defined as: 
𝐴 = 𝜀𝑏𝑐  (1) 
In which A is the absorbance (unitless, sometimes called “arbitrary units”), ε is the molar 
absorptivity with units of L mol
-1
 cm
-1
, b is the path
 
length of the sample (which is 1 cm for all 
samples), and c is the concentration of the compound in solution in mol L
-1
. Note that 𝜀 is 
dependent on the wavelength selected for a measurement, and will be different for a different 
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wavelength even if all else is constant. Given a constant cell path length and the same 
wavelength of absorption, the absorbance will be linearly related to the concentration of the 
species under study if Beer’s Law is valid. Beer’s Law is only valid in the so-called “linear 
regime”, where absorbance varies linearly with concentration. This relationship breaks down as 
absorbance increases above ~1.0. In general, this is because so little light is transmitted that 
changes in the amount transmitted are difficult to determine. Further discussion of the details of 
Beer’s law and the non-linearity issues will not be covered in this thesis.  
The binding or association constant (Ka) corresponds to the reaction Zn
2+
 + L ⇌ ZnL and 
can be easily determined if the concentrations of all components are known at equilibrium. 
Given that all of the individual concentrations of the species are difficult to determine in a 
complex solution mixture, we can consider the opposite reaction, which occurs when Zn(L) is 
dissolved in solution (see table 4.1), to obtain the Ka value. The process is explained in the 
following text. If the formal concentration of the zinc-ligand complex in solution is [𝑍𝑛𝐿] = 𝐶0,  
and the concentration change upon dissociation is [ZnL] = −x , then the final concentration 
when dissolved in solution will be [ZnL] = C0 − x.  
ZnL ⇌ Zn2+ + L 
Table 4.1. The concentration of each product and reactant in the equilibrium reaction. 
 (ZnL) Zn
2+
 L  
Expected concentration (C◦) C◦ (known) 0 0  
After equilibrium shift upon 
dissolving in solution 
-x +x +x  
The equilibrium 
concentration 
C◦ -x x x  
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In this study, the change in initial concentration the Zn(L) complex is reflected in the absorbance 
according to Beer’s Law:  
𝐴1 = 𝜀𝑏(𝐶0 − 𝑥) (2) 
Where the value A1 is the absorbance observed after Zn(L) was dissolved in solution. This 
absorbance is a result of the actual concentration of Zn(L) and x is the concentration of the 
dissociated amount of Zn(L) in solution. We are assuming that when a Zn(L) species is added to 
solution, some of the ligand dissociates according to Zn(L) ⇌ Zn2+ + L. When adding an excess 
of an additional Zn
2+
source such as ZnCl2, Le Chatlier’s principle should result in re-forming all 
of the Zn(L) species. The Beer’s Law equation will then become: 
𝐴2 = 𝜀𝑏(𝐶°) (3)  
Where A2 is the absorbance after sufficient amount of Zn
2+
 is added to drive all free ligand to 
completely form (ZnL). Therefore, the change in absorbance (ΔA) between the absorbance of 
just Zn(L) (A1) and the absorbance after adding Zn
2+
 to Zn(L) (A2) will be: 
∆𝐴 = 𝐴2 − 𝐴2 = 𝜀𝑏(𝑥)  (4) 
The molar absorptivity (ε) of the starting Zn(L) complex at the wavelength used is necessary for 
concentration calculations and be determined as follows: 
𝜀 =
𝐴2 
𝑏𝐶0
  (5) 
Once the molar absorptivity for a complex is obtained at the specific wavelength of study, the 
change in absorbance can been used to find the chance in concentration (x), using equation (6): 
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𝑥 =
∆𝐴
𝜀𝑏
        (6)  
 
In order to calculate the binding constant Ka, the increase of absorbance after adding Zn
2+
 
was obtained by subtracting the absorbance of the (ZnL) from the absorbance after additional 
Zn
2+
. The Ka was estimated by using the equations above and Table 4.1 combined in the 
equilibrium expression: 
𝐾𝑎 =  
(𝑍𝑛(𝐿))
(𝑍𝑛2+)(𝐿)
 =
(
𝐴°
𝜀𝑏
)
(
∆𝐴
𝜀𝑏
)(
∆𝐴
𝜀𝑏
)
  (7)    
𝐾𝑎 =
𝐴° .𝜀
(∆𝐴)2
  (8) 
Acetonitrile (ACN) was used as a solvent in some of the reactions due to the favorable 
short wavelength cutoff of 190 nm.
30
 All of the components in this study are soluble in ACN. In 
some cases, it was possible to use the same buffer solutions used in previous ITC experiments.
16
 
Analysis of the data was performed using Origin Lab software.   
 In addition to examining the (ZnL) interaction, we also examined the Zn-ligand 
interaction with inhibitors using UV-Vis spectroscopy and fluorescence spectroscopy. The 
chapter is divided in two sections based on the two approaches (UV-Vis and fluorescence 
spectroscopies) through which the interaction between Zn
2+
 and the ligands and between the Zn-
ligand complexes and the inhibitors were analyzed.  
4.1.2. UV-Vis spectra for the interaction between Zn
2+
 and ligands 
UV-Vis spectroscopy was used to examine zinc with several ligands. As shown in table 
4.2, the binding constant Ka values were generally in the range of 10
5–107 M-1 with a few 
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outliers. The binding constant for BPA (L2) in buffer was close to the values from ITC, which 
validates our results from this absorbance study.
16
 This also confirms that the affinity of the 
ligand to bind with Zn
2+
 is strong enough to be stable in further reactions with inhibitors.  
Table 4.2. Binding values between zinc and ligands studied using UV-Vis spectroscopy.  
 Solvent Co(M) ∆A A2 ε  x (M) ZnCl2 
(mg) 
Ka (M
-
1
) 
λmax 
(nm) 
Zn(L1) ACN 0.0010 0.011 1.26 1300 9.4×10
-6
 7.0 1.2×10
7
 280 
 Buffer 0.0010 0.029 1.48 1700 2.0×10
-5
 7.0 3.3×10
6
 260 
Zn(L2) Buffer 0.0020 0.0093 2.57 1300 7.3×10
-6
 7.0 3.7×10
7
 260 
 Buffer 0.0050 0.061 2.95 5700 1.0×10
-4
 7.0 4.2×10
5
 260 
 Buffer 0.50 0.14 2.95 5.5 2.5×10
-2
 7.0 6.9×10
2
 260 
Zn(L4) 
+(ZnCl2) 
ACN 0.0020 0.068 1.69 810 8.0×10
-5
 7.0 2.9×10
5
 250 
Zn(L4) 
+Zn(OAc)2 
ACN 0.0020 0.0015 1.31 660 2.3×10
-6
 7.0 3.8×10
8
 250 
 
In general, each spectra of each Zn component increases after adding an excess amount 
of Zn
2+
 and the maximum absorbance increases, corresponding with an increase in the 
concentration of the species. Notably, the absorbances of these compounds showed some 
differences. In Figure 4.1, the UV-Vis spectra of Zn(L1) showed one major absorbance. 
However, in Figure 4.2 there are multiple different peaks for Zn(L2)Cl2 in the absorbance. This 
is because of the overlapping in absorptions that happen at different electronic states. As shown 
in Figure 4.1 the λmax absorbance for Zn(L1) is at 280 nm. After adjusting the baseline, the 
absorbance spectrum was increased by 0.011 after the addition of ZnCl2. Therefore, using 
equation (7), the association constant Ka is 1.2×10
7
 M
-1
, if we take into account the 1:1 binding.  
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Figure 4.1. The UV-Vis spectra of Zn(L1). The λmax = 280 nm and the absorbance spectra of 
the Zn(L1) dissolved in 5 ml acetonitrile has an absorbance of 1.29 (black). The red spectra show 
absorbance (with a value of 1.32) after adding ZnCl2 (7.0 mg) at the same λmax. 
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Figure 4.2. UV-Vis spectra of Zn(L2) with concentrations of 1 mM, 2 mM, 5 mM and 500 
mM (A, B, C, and D, respectively). Spectra in black show the asborbance of Zn(L2), with 
absorbances are at 1.69, 2.55, 2.89 and 2.89 respectively. The red spectra show the absorbance of 
Zn(L2) with the additional of ZnCl2, with absorbances at λmax increasing by 0.05, 0.004, 0.07 and 
0.16 respectively. All products were disoloved in 5 ml buffer. 
 
The equilibrium association constant obtained from ITC experiments for Zn(L2) (2.4×10
7 
M
-1
) 
was close to those obtained by UV-Vis experiments.
16
 With increasing the concentration of 
Zn(L2), the absorbance increases, because of Beer’s Law. However, at higher concentrations 
Beer’s law may not be valid.30 Four concentrations of Zn(L2) were examined in buffer:1 mM, 2 
mM, 5 mM and 500 mM. All spectra showed λmax of 260 nm with increasing values of 
absorbance. The Zn(L2) shows a Ka of 3.3×10
6 
M
-1
, 3.7×10
7 
M
-1
, 4.2×10
5
 M
-1
 and 6.9×10
2 
M
-1
, 
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respectively from these four concentrations. The Ka values derived from runs with absorbances > 
2 are probably incorrect due to deviations from Beer’s Law. At these high absorbances, the 
percent of total transmitted light becomes very low, so attempting to observe accurate changes in 
the amount of that light is not possible.  
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Figure 4.3. The UV-Vis spectra of Zn(L4) . The λmax is 250 nm and the absorbance at λmax is 
1.62 (black). The addition of Zn
2+
(red) as ZnCl2 increases the spectra by 0.070 at the same 
wavelength (plot on the left). The spectra on the right, show the spectra of Zn(L4) at the same 
concentration, but with added Zn(OAc)2. The λmax is 250 nm and the absorbance increases by 
0.01.  
 
We were curious to see how different zinc salts might affect the UV-Vis measurements. 
When ZnCl2 was used with Zn(L4), the Ka was ca. 2.9×10
5 
M
-1
. However, with the addition of 
Zn(OAc)2, the absorbance increases by 0.018 and the association constant was 3.8×10
8
 M
-1
, 
higher in value than using ZnCl2. These numbers are estimates, and show that care must be taken 
when making comparisons between systems to use the same zinc source. In addition, large 
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absorbance values (> 1) have so little transmittance that the numbers become less accurate and 
Beer’s law may not be valid. Therefore, these numbers should be calculated again with more 
dilute solutions in future studies. The rows in Table 4.2 with final absorbance values above 2 are 
likely not useful runs.   
In order to check our assumption that adding Zn
2+
 resulted in complete reformation of 
Zn(L), we calculated the amount of dissociation of Zn(L) in the presence of ZnCl2 using the Ka 
values we obtained (see Table 4.2). The equilibrium reaction is shown below, along with table 
4.3, which includes a term for the concentration of added Zn
2+
 (z). 
Zn
2+
 + L ⇌ ZnL  
Table 4.3. The concentration of each product and the reactant in the equilibrium reaction 
after adding ZnCl2. 
 Zn
2+ 
Ligand (ZnL) 
The concentrations after 
adding ZnCl2 
z 0 Cₒ 
After equilibrium shift upon 
dissolving in solution 
+y +y -y 
The equilibrium 
concentration 
z+y y Cₒ-y 
 
Therefore, the equilibrium expression for Ka from the values in Table 4.3 will be: 
𝐾𝑎 =
𝐶° −𝑦
(𝑧+𝑦)(𝑦)
  (9) 
For our UV-Vis analysis to be correct, we need to know that y is sufficiently small compared to 
Cₒ. Assuming y is small compared to Cₒ and to z, we can simply and solve for y according to the 
following relationship:  
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 𝑦 =
𝑧
𝐾𝑎.𝐶° 
  (10) 
This allows us to check that our approach would work by verifying that y is very small compared 
to Co. Table 4.4 shows the results of this analysis, including the % value of y compared to Co. As 
can be seen, the % value of y compared to Co
 
is always less than 1%, verifying that our 
assumption was valid. In other words, the amount of Zn
2+
 added was enough to ensure that the 
ZnL species were completely reformed in our UV-Vis studies. 
Table 4.4. The concentration values after adding an excess amount of ZnCl2.  
 z (M) C◦(M) x (M) y % 
Zn(L1) 0.010 0.0010 9.4×10
-6
 8.5×10
-7
 0.085 
 0.010 0.0010 2.0×10
-5
 3.0×10
-6
 0.30 
Zn(L2) 0.010 0.0020 7.3×10
-6
 1.4×10
-7
 0.0068 
 0.010 0.0050 1.0×10
-4
 4.8×10
-6
 0.096 
 0.010 0.50 2.5×10
-2
 2.9×10
-5
 0.0058 
Zn(L4) +(Zncl2) 0.010 0.0020 8.0×10
-5
 1.8×10
-5
 0.88 
Zn(L4) +Zn(OAc)2 0.010 0.0020 2.3×10
-6
 1.3×10
-8
 0.00065 
 
4.1.3. UV-Vis spectra of interactions between (ZnL) and inhibitors 
In this section the interaction between (ZnL) and inhibitors were studied using UV-Vis 
spectroscopy. Because of the UV-Vis spectra of isolated (ZnL)-inhibitor structures are not 
known, the binding constants could not be obtained, but qualitative changes in the spectra were 
observed. In order to find Ka values, the stoichiometry of the reaction with inhibitors as well as 
the molar absorbtivities of the ZnL-inibitor ternary complexes would be needed. 
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Table 4.5. UV-Vis spectra of (ZnL) and inhibitors species.  
250 260 270 280 290 300 310 320 330 340 350 360 370
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
A
b
s
o
rb
a
n
c
e
 (
u
n
it
le
s
s
)
Wavelength (nm)
 
Figure 4.4. UV-Vis spectra of Zn(L1)(8HQ) and 8HQ with the addition of Zn(L1)(8HQ) in 
ACN at a concentration of 0.050 mM. The black spectrum represents 8HQ alone, and the λmax 
is 308 nm with an absorbance of 2.36. The addition of Zn(L1)(8HQ) (red),  results in an increase 
in the spectra by 0.11 at the same wavelength, as well as the appearance of new peaks. 
 
In order to examine the reaction of Zn(L1) for 8HQ, the UV-Vis spectra were taken for 
the 8HQ as well as a combination of Zn(L1) and 8HQ. In Figure 4.4, the black spectrum of 
shows a λmax of 308 nm and an absorbance value of 2.36. The spectrum of Zn(L1)(8HQ) was 
significantly different from that of just Zn(L1), indicating that we likely formed a complex 
between Zn(L1) and 8HQ. However, the identity of the species is unknown based solely on this 
Complex ∆A 
 
Cᵒ 
(mM) 
Inhibitor 
(mg) 
λmax  
(nm) 
Zn(L1)-SAHA 0.58 0.050 3.0 240 
Zn(L1)-8HQ 2.4 0.050 7.0 308 
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UV-Vis data and the NMR data in chapter 3. We hope that X-ray crystallography can be used in 
the future to determine the structure of the compound. 
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Figure 4.5. The UV-Vis spectra of Zn(L1)(SAHA) (black) and with addition of SAHA (red) 
in ACN. For the black spectrum, the λmax is 241 nm and the absorbance at λmax is 0.68. The 
addition of 8HQ (red), as 8HQ increases the spectra by 0.55 at the wavelength 240 nm.  
 
Likewise, the interaction between Zn(L1) and SAHA was examined by using UV-Vis, at 
a concentration of 0.05 mM, the absorbance spectrum was obtained with a λmax = 241 nm. Upon  
addition of SAHA the absorbance at 241 nm was increased by 0.5. The association constant for 
this reaction could not be calculated due to the unknown stoichiometry of the resulting complex 
Zn(L1) and SAHA and the unknown molar absorptivity.  
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Figure 4.6. UV-Vis spectra of Zn(L2) and 8HQ. The spectrum in black indicates the 
absorbance of the Zn(L2) and 8HQ in concentration of 0.05 mM and the spectrum in red 
indicates the absorbance after the addition of 8HQ. For the black spectrum, the λmax is 307 nm 
and the absorbance at λmax is 1.57. The addition of 8HQ (red), as 8HQ increases the spectra by 
1.15 at the wavelength 308 nm.  
 
The interaction between Zn(L2)Cl2 and 8HQ was studied using UV-Vis spectroscopy. The UV-
Vis spectra show that the absorbance of the complex Zn(L2) and 8HQ was increased by 1.2 after 
adding a fixed amount of 8HQ (2.0 mg), but the data does not provide any insight into clear 
binding. Given the limited data that could be obtained from the UV-Vis studies of inhibitors 
reacting with the zinc complexes, we therefore turned to fluorescence spectroscopy.  
 
 
 
62 
4.2. Examining the binding of Zn
2+ 
with ligands and inhibitors by using fluorescence 
spectroscopy  
4.2.1. Introduction  
Fluorescence is defined as the emission of photons from an excited energy states as the 
system returns to a lower electronic state, such as in 𝑆1 → 𝑆0 (Figure 4.7). If a certain species can 
absorb a specific energy of electromagnetic radiation, its electrons will be driven to a higher 
energy states (excitation). The absorbance as a function of wavelength yields an absorbance 
spectrum. However, these higher electronic energy states are unstable. Thus, the excited 
electrons will decay to their original lower energy states, which can result in the emission of light 
if they undergo a luminescence process. It should be noted that the wavelength of fluorescence 
emission should be higher than the absorbance wavelength, because the energy in the emission 
process is lower than in the absorbance process (some energy is always lost to relaxation 
processes that do not emit UV-Vis radiation).
31 
In other words, the energy of the emitted light is 
always lower than the absorbing light because of the relationship between energy and 
wavelength: 
𝐸 =
ℎ𝑐
𝜆
  (9) 
In which E is the photon energy, λ is the wavelength (nm), h is the Planck constant and c is the 
speed of light. Each photon released has its characteristic energy and it can be determined by 
subtracting the energy of the excited state and the energy of the ground state. Therefore, the gap 
between energy levels defines the photon energy. The fluorescence spectrometry for Zn-ligands 
is determined by the π – electrons of the conjugated organic ligand, because zinc does not have 
fluorescence character in the UV-Vis regions.
32
 Fluorescence experiments were conducted to 
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study the interaction between 8HQ and SAHA with various ligand-Zn
2+
 binary complexes that 
had been identified as potential HDAC functional mimetics based on the ligand and Zn
2+ 
ITC 
and UV-Vis studies. All complexes were dissolved in DMSO in very small amounts (sometimes 
the solution needed to be further diluted in order to detect the fluorescence emission signal on the 
scale of the spectrometry). Due to the small amounts used and the limits of accuracy on the 
balances, we did not determine the concentration of the solution. The data is presented without 
normalization, which may exaggerate the comparison of emission intensities. Because 
quantification was not possible, only qualitative changes in emission spectra were examined.   
 
 
Figure 4.7. Example Jablonski diagram for organic dyes: IC—internal conversion, ESA—
excited state absorption, ISC—intersystem crossing.3 
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4.2.2. Fluorescence spectra of Zn-ligand and inhibitor interactions  
Three wavelengths were selected for fluorescence excitation: 240 nm, 260 nm, and 310 
nm. The first two are excitations in the UV region where most of the compounds have 
absorption, and the 310 nm corresponds to absorption peaks in some of the Zn(L) complexes. 
These three values were kept consistent in order to make qualitative comparisons of the emission 
spectra. The fluorescence spectrum of the SAHA inhibitor was first obtained in order to compare 
with the zinc complexes (Figure 4.9). At an excitation 310 nm, a weak emission at λmax = 479 nm 
is observed (blue). Exciting at 240 nm yields no detectable emission. At an excitation of 260 nm, 
the spectrum displayed “negative emission”, which is not an emission of SAHA, but rather likely 
noise. Both the positive and “negative” fluorescence intensities were very small.  
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Figure 4.8. The fluorescence emission wavelengths of free SAHA at excitation wavelengths 
240, 260 and 310 nm.  
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The fluorescence emission spectrum of Zn(L1) and SAHA was then recorded. The 
reaction was prepared by dissolving both compounds in DMSO. In the Figure 4.10, at excitation 
wavelength of 240 nm, the emission maximum was at 375 nm. The sharp peak observed at 484 
nm is an artifact of the data collection. Often, sharp peaks are the harmonic of the excitation 
spectrum or other artifacts, and should not be considered to be emissions from the excited 
compounds. Exciting at 260 nm (not shown) resulted in no detectable emission. Exciting at 310 
nm resulted in a sharp peak at 572 nm (likely an artifact) and a broad emission at 425 nm. The 
peak at 572 nm was observed as an unidentified artifact in several of our fluorescence spectra. 
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Figure 4.9. The Fluorescence spectra of Zn(L1) and SAHA interaction. The spectrum in red 
shows the emission in 310 nm, and the spectrum in black shows an emission with excitation at 
240 nm.    
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The Fluorecsence spectra of Zn(L2), shown in Figure 4.11, showing one emission peak at 
496 nm upon excitation at 240 nm. At 260 nm there was no observed emission, and at 310 nm 
three peaks were observed at 401 nm and 337 nm, as well as an artifact at 570 nm (Figure 4.10). 
When 8HQ was used as the inhibitor with Zn(L2) in DMSO, shown in Figure 4.12, emission 
peaks were observed at all 3 excitation wavelengths studied. At an excitation of 240 nm, only a 
small emission at 530 nm was observed. However, at 260 nm excitation, strong emission was 
observed at 492 nm. At 310 nm excitation, the emission at 492 nm moved to 482 nm, and small 
emission appeared at 344 nm as well. At excitation with 260 nm, Zn(L2) did not show emission. 
However, Zn(L2)(8HQ) shows two different emission peaks at higher wavelengths at this 
excitation. The fluorescence spectrum of free 8HQ (Figure 4.12) does not show the same peaks 
seen at all three excitations of Zn(L2) with 8HQ. Comparing emission of 8HQ and emission of 
Zn(L2)(8HQ), we can determine that there is some form of binding between Zn(L2) and 8-HQ 
based on the qualitative emission changes. In addition, these emission spectra were different 
from the emissions of just Zn(8HQ)2 (Figure 4.15). 
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Figure 4.10. The fluorescence emission of Zn(L2) at excitations of 240 nm and 310 nm.  An 
emission is observed at 400 nm upon excitation at 310 nm.  
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Figure 4.11. The fluorescence spectra of Zn(L2) with 8HQ in DMSO. Three emission spectra 
were observed after exciting the complex at excitations 240, 260 and 310 nm.  
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Figure 4.12. Fluorescence spectra of 8HQ. At excitation wavelengths 240, 260 and 310 nm. 
The product was dissolved in DMSO. An emission was observed at around 400 nm, but the 
spectral window examined did not allow for the peak wavelength to be observed. 
 
When the isolated Zn(L3)OH species was studied in DMSO for fluorescence, the significant 
emissions were observed at 240 nm are a large  two peaks at 584 and 606 nm (likely a 
vibrational progression, Figure 4.14). At 260 nm excitation, an emission at 706 nm was 
observed. At 310 nm, only a likely harmonic artifact was observed.  
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Figure 4.13. Fluorescence emission of Zn(L3)OH in DMSO at excitations of 240 and 310 
nm. An emission was observed at around 400 nm at excitation 240 nm, but the spectral window 
examined did not allow for the peak wavelength to be observed. The peak observed at 622 nm is 
likely a harmonic of the excitation at 310 nm. 
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Figure 4.14. The fluorescence spectra of Zn(L3)(8HQ) in DMSO. Different emission 
behavior was observed after exciting the complex in 240, 260 and 310 nm. 
The fluorescence spectra of Zn(L3(8HQ) show two major peaks at excitation 240 nm and one 
small peak at excitation wavelength 310 nm, along with the double harmonic of the excitation 
wavelength. In order to attempt to understand the spectra of Zn(L3)(8HQ), the known 
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Zn(8HQ)2 species was studied with fluorescence. Zn(8HQ)2
 
showed different behavior 
compared to Zn(L3)OH and Zn(L3)(8HQ) in that the same emission at 351 nm was observed 
at all 3 excitation wavelengths (Figure 4.15). Interestingly, at excitation with λ = 260 nm a 
new emission peak appeared at 543 nm as well.  
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Figure 4.15. Fluorescence spectra of Zn(8HQ)2. As shown the emissions of all excitations 
contain a feature at 351nm. There is also a clear broad peak at 543 nm upon excitation with 260 
nm light. Other features are artifacts or harmonic peaks of the excitation wavelengths.  
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Figure 4.16. Fluorescence spectra of ZnCl2 and SAHA. Both excitations studied did not result 
in significant emission signals (the sharp signals are artifacts).  
The fluorescence spectra of the reaction mixture containing ZnCl2 and SAHA were 
obtained at excitations 240 nm and 310 nm (Figure 4.16). Unfortunately, there were artifacts in 
the emission spectra but no clear major peaks.(similar to the fluorescence spectrum of SAHA). 
SAHA is inactive to fluorescence spectroscopy compared to 8HQ, which is likely due to the lack 
of conjugation in SAHA as compared to 8HQ. 
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Figure 4.17. The fluorescence spectra of Zn(L4) and 8HQ at excitation wavelengths 240, 
260 and 310 nm. A major feature at 550-560 nm is seen at excitations of 260 and 310 nm. 
 
In Figure 4.18, the fluorescence spectra of Zn(L4) and 8HQ at all three excitation wavelengths is 
shown. At excitation with240 nm (black), the spectrum shows no major emission. However, at 
excitation with 260 nm, an emission peak was shown at wavelength 551 nm as well as a peak 
near 400 nm, and at excitation 310 nm, an emission shows at 555 nm wavelength. Comparing the 
fluorescence spectra of Zn(L4) and 8HQ with the fluorescence spectra of free 8HQ, there are 
clear differences, indicating that 8HQ can react with Zn(L4).   
  In conclusion, UV-Vis spectroscopy and fluorescence spectroscopy were used to study 
the zinc complexes and their interactions with inhibitors. UV-Vis spectroscopy of the (ZnL) 
compounds in the presence of added zinc was used to estimate Ka values, which agreed 
reasonably well with ITC values in the case of BPA. However, the absorption values were high, 
and should be re-examined under more dilute conditions. Fluorescence was used to examine 
inhibitor interactions with zinc complexes, and 8HQ showed strong changes in responses when 
coordinated to zinc, whereas SAHA was found to not be very responsive to excitation in 
fluorescence spectroscopy. The fluorescence studies of the (ZnL) mimetic complexes and their 
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binding with inhibitors provide valuable information. We observed qualitative changes in the 
emission spectra of the various complexes in the presence of inhibitors, indicating that reactions 
were observed. Fluorescence of Zn(L1) and 8HQ showed emission spectra at 375 nm that was 
not observed with free 8HQ. When comparing the emission spectra of the reaction between 
Zn(L2) and 8HQ with the emission spectra of free 8HQ (Figure 4.12), the spectra also did not 
match. For the interaction between Zn(L3)OH with 8HQ (Figure 4.14), the emission spectra 
were different comparing to the emission spectra of free 8HQ or Zn(8HQ)2 (Figure 4.15). Lastly, 
the Zn(L4) with 8HQ (Figure 4.17) show emission spectra that is also different than the 
fluorescence spectra of free 8HQ or Zn(8HQ)2. We can conclude that Zn(L4) binds to 8HQ in 
solution and forms a product that is different than Zn(8HQ)2. The data with SAHA were less 
conclusive because of the lack of significant fluorescence response from SAHA. Notably, 
quantitative studies of these and related complexes would be more informative, wherein the 
concentrations of all species are known and the extinction coefficients of the emission spectra 
can be determined. Further studies are also needed to understand the mechanism of the 
fluorescence from these compounds. Work toward these goals is ongoing in the Grice lab.  
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